| In partnership with |  |
| Good day, 360! Did you know you have LIVE teaching and trading with a 20+ year seasoned trader right at your fingertips. | Join Jeff Williams in our Market Masters chat room this morning from 9am to 11am to watch and listen as he breaks down markets and some of the hottest penny stock movers today. | Hundreds of like minded traders all working to beat the odds. | | FOCUS LIST🔎 | TVGN - Up over 30% in pre, after closing yesterday up over 54% on announcement that Tevogen AI Joined Microsoft for Startups, and begins accelerating drug development | TSLA - Up over 12% in pre after earnings beat, strong guidance | DBVT - Up over 20% in pre after announcing positive regulatory updates for the Viaskin® Peanut Patch in the United States and Europe | | *Sponsored by ESGold | Keep This Gold Stock on your Watchlist 🇨🇦 $ESAU 🇺🇸 $SEKZF | | Gold prices hit an all-time high ESGold stock is up over 50% this month Committed to eco-friendly mining practices
| Read More | Disclaimer: This ad is paid for and disseminated on behalf of ESGold Corp (it is sponsored content). We do not own any securities of ESGold Corp. This ad contains forward-looking statements, which are not historical facts. These statements are based on the current beliefs and expectations of ESGold Corp's management and involve known and unknown risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions often identify forward-looking statements. This is not financial advice, please do your own DD. See SEDAR+ for more information. |
|
| | HOTLIST🔥 | TVGN - Up over 30% in pre, after closing yesterday up over 54% on announcement that Tevogen AI Joined Microsoft for Startups, and begins accelerating drug development | Tevogen Bio (TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. | In the pre-market yesterday, the company announced its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft's extensive ecosystem. | The partnership is set to accelerate and streamline the development of Tevogen's proprietary algorithms, significantly advancing its mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations. | Shares of TVGN closed yesterday up over 54% and traded up another 30% in the pre-market this morning in reaction to the news. | | The $3.03 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $3.15, $3.25, $3.30 and then the pre-market high at $3.40. Beyond that, $4 and $4.78 come into play. | Below $3.03, targets to the downside are $2.72, and then a gap fill at $2.48 with $1.87 and $1.61 below that. | | TSLA - Up over 12% in pre after earnings beat, strong guidance | Tesla Inc. (TSLA) designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. | In the after-hours yesterday, the company reported Q3 2024 financial results. | Highlights Include: | Net income for the quarter increased by 8% compared to the year-ago period to $2.5 billion vs $2.1 billion prior | Revenue was up 8% to $25.2 billion, just under estimates | Gross margins excluding credits, a closely watched performance metric, rose to 17.05% from 14.7% in the prior quarter, an improvement partly driven by declining manufacturing costs and freight expenses. | Tesla said that it expects to achieve "slight growth" in vehicle deliveries in 2024, while Musk predicted cost cuts and lower interest rates would spur vehicle sales growth of 20% to 30% next year. | Tesla also noted that preparations for new vehicle launches remain underway, adding it continues to expect to roll out more affordable models in the first half of 2025. | Shares of TSLA traded up over 12% in the pre-market after the better than expected guidance. | | The first target for bulls is the pre-market high at $244.27. | Beyond that, targets to the upside are $247.43, $250, $251.16 and then a gap fill at $258.02. | Below $243.40, targets to the downside are $241.35, $238.77, $233, $230, $227 and then $223.50. | | What are the HOTTEST stocks to be looking for right now? | Penny Stocks! |  | *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| JW hunts down the hottest movers during "Power Hour" every day in his live trading room called the "War Room." | Real time trading lessons, scanning techniques and real money trades. | All right here, right now. |
|
| | DBVT - Up over 20% in pre after announcing positive regulatory updates for the Viaskin® Peanut Patch in the United States and Europe | DBV Technologies S.A. (DBVT) is a clinical-stage biopharmaceutical company that engages in the research and development of epicutaneous immunotherapy products. | In the after-hours yesterday, the company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. | Highlights Include: | DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old | BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 | VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 | European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe | The stock traded up over 20% in the pre-market in reaction to the news. | | The $0.86 area acted as resistance in the pre-market and will be an important level to watch. | Above it, targets to the upside are $0.95 and then the pre-market high at $1.04. Beyond that, $1.09, $1.20 and $1.30 come into play. | Below $0.86, targets to the downside are $0.77, and then a gap fill at $0.6801. | | MARKET NEWS 📰 | | | | P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar